EpHLA software: A timesaving and accurate tool for improving identification of acceptable mismatches for clinical purposes

Filho, Herton Luiz Alves Sales; Sousa, Luiz Cláudio Demes da Mata; Glehn, Cristina de Queiroz Carrascosa von; Silva, Adalberto Socorro da; Neto, Pedro de Alcântara dos Santos; Nascimento, Fernando Ferraz do; Castro, Jose; Nascimento, Liliane Machado do; Kneib, Carolina; Cazarote, Helena B.; Kitamura, Daniele M.; Torres, Juliane Roberta Dias; Lopes, Laiane da Cruz; Barros, Lexlanna Aryela Loureiro; Edlin, Evelin Nildiane da Silva; Moura, Fernanda Sá Leal de; Watanabe, Janine Midori Figueiredo; Monte, Semíramis Jamil Hadad do

doi:10.1016/j.trim.2012.02.006

Cited by 11 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The automated generation of reports requires the integration of files containing the results of laboratory tests (HLA typing, anti‐HLA antibody signature) and public data banks (International ImMunoGeneTics information system – IMGT and National Marrow Donor Program – NMDP ). The efficiency of this software for identifying acceptable mismatches for highly sensitized patients has already been demonstrated on renal transplant patients, as has the superiority of this software compared to the manual use of the HLAMatchmaker algorithm regarding accuracy and speed of the analysis . It is important to know that HLA typing is an essential component of a successful kidney transplant program: HLA system plays a central role in the cellular and humoral immune responses that determine the outcome of a transplant and the extensive polymorphism of HLA poses a major barrier to successful transplantation .…”

Section: Introductionmentioning

confidence: 99%

The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness

et al. 2015

View full text Add to dashboard Cite

show abstract

“… 13 The efficiency of this software in identifying acceptable incompatibilities in alloimmunized patients has been previously demonstrated in renal transplant patients and is more efficient than the manual use of HLAMatchmaker with regard to accuracy and speed of analysis. 12 The use of EpVix software in selecting platelet donors has also been demonstrated recently 8 ; it proved to be a powerful search tool for HLA donors compatible with patients who are refractory to platelet transfusions.…”

Section: Introductionmentioning

confidence: 99%

“…Based on HLAMatchmaker, a Brazilian research team has developed a software that was first called EpHLA and later renamed EpVix (platelets.epvix.com.br). 12 The platform simplifies the identification of compatible donors or donors with acceptable incompatibilities. The software is easy to use and identifies strongly immunogenic, weakly immunogenic and non-immunogenic epitopes in HLA alleles.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Applicability of an instrument to identify human leukocyte antigen-compatible donors for platelet transfusions

Ferreira

Vito

Ferreira

et al. 2018

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

BackgroundThe selection of compatible human leukocyte antigen platelets has been associated with improved platelet increments. Therefore, an effective strategy would be the selection of donors who are genetically compatible according to the human leukocyte antigen system. Nonetheless, this is costly as it concerns a highly polymorphic system, which requires a large bank of genotyped donors.MethodsThis study evaluated the feasibility of virtual crossmatching using EpVix software, which simplifies the identification of compatible donors or donors with acceptable incompatibilities.ResultsForty-three oncohematological patients were evaluated, in 96 platelet transfusion episodes with 16.3% of the patients being found to be refractory to platelet transfusions. Eight alloimmunized, multitransfused patients were selected to evaluate human leukocyte antigen compatibility against a bank of 336 platelet donors. At least partially compatible donors were found for all patients. The number of compatible donors was found to be inversely proportional to the human leukocyte antigen-panel reactive antibody score of each patient. It was noted that five patients with scores of 15% or less had at least 190 compatible donors; four fully compatible donors were found for two other patients with scores greater than 80% and only one patient (score of 93%) did not have a fully compatible donor. However, for this last patient, 40 donors were partially compatible according to the software.ConclusionThe results showed the effectiveness of the use of the EpVix tool to identify potential platelet donors for multitransfused and/or alloimmunized patients, even with a small number of human leukocyte antigen genotyped donors available.

show abstract

“…http://epvix.com.br/). The efficiency of this software for identifying acceptable mismatches for highly sensitized patients has already been demonstrated on renal transplant patients, showing its superiority over the manual use of the HLAMatchmaker algorithm regarding the accuracy and speed of analysis [4]. A improved Web version of EpHLA, named Epvix, was introduced by the same group, initially directed to kidney transplant donor selection and then adjusted to HLA platelet compatible donor selection (https://platelets.epvix.com.br/).…”

Section: Introductionmentioning

confidence: 99%

Virtual platelet cross‐matching as transfusion management for patients with immune platelet refractoriness

Bonet‐Bub,

Blanco,

de Oliveira

et al. 2023

Vox Sanguinis

View full text Add to dashboard Cite

Background and ObjectivesThis study describes the use of the Epvix platform for virtual cross‐matching (VC) of human leucocyte antigen (HLA)‐compatible platelets for patients with immune platelet refractoriness, and demonstrates effectiveness of the selected platelets.Materials and MethodsA prospective cohort of haematological patients was evaluated from 2018 to 2022. HLA‐typed donor bank profile was previously uploaded to the Epvix platform. Each patient's antibody reactivity panel (PRA) was included in the platform. Then, search, selection and VC were performed, and 24‐h‐corrected count increment (CCI) platelet transfusion was calculated (reference ≥2500).ResultsSix patients were included (four female, two male), with mean age of 61 years. HLA antibodies were detected as the cause of immunity for all patients, whereas four patients also had non‐immune causes. High percentage of alloimmunization was detected in all studied patients (mean PRA: 85.7%). Thirty different donors were able to schedule and perform platelet donations. The mean 24‐h CCI count was 9882. All platelet transfusions achieved a satisfactory CCI count except for two transfusion events. Presence of non‐immune causes identified in these two cases could account for the unsatisfactory CCI.ConclusionEpvix is a free application hosted on the Web and uses the HLAMatchmaker algorithm to generate histocompatibility reports. This study demonstrates the efficiency of VC performed by Epvix. However, physical cross‐matching will still be necessary in some instances, as the platform does not support human platelet antigen polymorphism.

show abstract

EpHLA software: A timesaving and accurate tool for improving identification of acceptable mismatches for clinical purposes

Abstract: The EpHLA software is an accurate and quick method for the identification of AMMs and thus it may be a very useful tool in the decision-making process of organ allocation for highly sensitized patients as well as in many other applications.

Cited by 11 publications

References 15 publications

The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness

The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness

Applicability of an instrument to identify human leukocyte antigen-compatible donors for platelet transfusions

Virtual platelet cross‐matching as transfusion management for patients with immune platelet refractoriness

Contact Info

Product

Resources

About